ImprimisRx CA, Inc., dba ImprimisRx – FDA 483, Mar 31, 2017
ImprimisRx CA, Inc., dba ImprimisRx in Irvine, CA, was cited for three observations during an FDA inspection concerning sterile drug production. Deficiencies included inadequate aseptic processing area controls with compromised air quality, insufficient complaint record investigations and follow-up, and a quality control unit lacking full authority to investigate errors. These issues indicate significant concerns regarding the firm's quality systems and sterile drug production.
ID · 62ac1347-3110-425f-aef3-39a6b725cfc1
Full citation text and observation details available on the Dashboard.
Document or profile
One record shows the event. A profile shows the pattern.
Buy this document for the source file and details behind this single event.
Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.